The Securities and Exchange Commission (SEC) has accused Immunosyn Corp., the makers of a bogus drug made from goat’s blood, of cheating investors of $20 million, the Courthouse News Service reports. The SEC also accuses the company of hiding from investors the fact that the Food and Drug Administration had twice stopped human trials of the drug, which is called SF-1019. The company claimed the drug could treat numerous ills, including HIV/AIDS, chronic inflammatory demyelinating polyneuropathy, diabetic neuropathy and diabetic ulcers.

To read the Courthouse News article, click here.